ZURICH (Reuters) – Medical regulator Swissmedic is extending the temporary ordinary authorisation of the Pfizer/BioNTech coronavirus vaccine to include young people aged between 12 and 15, the agency said https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/covid-19-impfstoff-pfizer-biontech-fuer-jugendliche.html on Friday.
(Reporting by Michael Shields; Editing by Alison Williams)
